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Rubella virus is a common cause of childhood fever and rash.
It is of public health importance largely owing to the
teratogenic effects of primary or secondary rubella infection in
the first trimester of pregnancy.1 Rubella acquired in the first 12
weeks of pregnancy is associated with a nearly 90% risk of
congenital malformations.2 A highly effective vaccine has been
available since 1969 and vaccination programmes have
eliminated or greatly reduced the incidence of rubella and
congenital rubella syndrome (CRS) in developed countries.3
Information on the epidemiology of rubella in South Africa is
somewhat lacking. An article published in the December 1977
issue of the SAMJ by Kipps et al.4 entitled ‘The epidemiology of
rubella in Cape Town’ began as follows:  ‘Information on the
epidemiology of rubella in the Republic of South Africa is
woefully incomplete. The disease is not notifiable and there are
no available reports of nationwide epidemics or of the
incidence of congenital rubella infections in the general
population.’4 Regrettably little has changed in the subsequent
28 years. Currently there is no national rubella immunisation
programme, rubella is not notifiable, there are no surveillance
programmes for congenital rubella, and the percentage of non-
immune women of childbearing age is largely unknown. The
1977 study by Kipps et al. showed that 8.5% of females aged
between 15 and 25 years living in Cape Town were not
immune to rubella. A small study in 1983 from Tygerberg
Hospital5 showed that 10.5% of female hospital staff were
susceptible to rubella. Data collected by Johnson et al.6 in 1985
from the former Witwatersrand area on random serum
specimens submitted to the former National Institute for
Virology showed that a worrying 18.4% of women of child-
bearing age were non-immune. In other developing countries
the proportion of women of childbearing age susceptible to
rubella varied from 4% in China to 70% in Trinidad and
Tobago.7
This study was prompted by a retrospective view which
revealed that our virology laboratory at Groote Schuur
Hospital confirmed 20 cases of congenital rubella syndrome
over the 30 months from April 2002 to October 2004.  In
addition we are frequently asked to investigate cases of
probable primary rubella or rubella reinfection in early
pregnancy. Knowledge of rubella seroprevalence would allow
one to model the incidence of CRS, thus providing an indirect
measure of the burden of CRS. This is essential information for
health policy makers when considering the inclusion of the
rubella vaccine in the routine Expanded Programme for
Immunisation in South Africa (EPI (SA)) schedule. We
investigated the prevalence of immuno- globulin G (IgG)
antibodies to rubella virus in 1 200 serum samples obtained
from the 2003 Department of Health antenatal HIV/syphilis
serosurvey within the Western Cape, South Africa.8 The present
study is the first systematic study of rubella seroprevalence in
pregnant women to have been performed in South Africa.
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Objectives. To determine the seroprevalence of rubella virus
infection among antenatal patients aged between 15 and 45
years in the Western Cape province of South Africa, in order to
provide data to determine the need for vaccination to protect
women of childbearing age.
Design. A cross-sectional study.
Setting. Virology laboratory, Groote Schuur Hospital, National
Health Laboratory Service (NHLS), South Africa.
Subjects and methods. One thousand two hundred provincial
serum specimens from participants in the 2003 Department of
Health antenatal HIV/syphilis serosurvey were selected from
the 4 districts of the Western Cape.  The specimens were age-
stratified and screened qualitatively for rubella immunoglo-
bulin G (IgG) antibodies by means of a commercial
immunoassay during October 2004.
Results. Within the Western Cape a total of 95.3% of women in
the 15 - 24-year age group, 97.5% in the 25 - 34-year group and
98% in the 35 - 45-year age group were immune to rubella.
There was no statistically significant difference in the rate of
rubella susceptibility between the 4 districts tested.
Conclusions. The study is an important step in addressing the
seroprevalence of rubella infection in women of childbearing
age in South Africa. Further information is needed on rubella
seroprevalence from the other provinces in South Africa as well
as formal implementation of rubella and congenital rubella
syndrome surveillance to determine the feasibility of routine
rubella immunisation.
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Materials and methods
Study population
One thousand two hundred provincial serum samples from
participants in the 2003 Department of Health antenatal
HIV/syphilis serosurvey were analysed for rubella IgG
antibodies. These samples had been stored at −20oC following
testing for HIV and syphilis. The Western Cape covers an area
of roughly 129 370 km2 and has a population of approximately
4.5 million people.9 For the purposes of the annual antenatal
survey the province is divided into 4 districts, namely the
Metropolitan, West Coast/Winelands, South Coast/Klein
Karoo and Boland/Overberg districts (Fig. 1). The Central
Karoo district is not included in the Western Cape for the
HIV/syphilis serosurvey and was therefore not included in this
study. Three hundred anonymously collected serum specimens
from women from each of the 4 districts were stratified
according to age and tested for rubella IgG antibodies.  The
study was approved by the Research Ethics Committee of the
University of Cape Town. 
Enzyme-linked immunosorbent assay (ELISA) for
measuring antibodies to rubella
Rubella-specific IgG antibodies were screened for qualitatively
using a commercial immunoassay (Dade Behring, Marburg,
Germany). The procedure and the interpretation of the results
were performed according to the manufacturer’s instructions.
Specimens with equivocal results were re-tested in duplicate.
An optical density reading of > 0.2 at 450 nm was interpreted
as positive for rubella IgG. Women with negative or equivocal
results were regarded as being non-immune to rubella. 
Results
A total of 1 200 serum specimens (300 from each district) were
tested and included in the analysis. The combined results from
all 4 districts tested are shown in Table I.
The age-stratified results from each district are shown in
Table II. Combining the results from the 4 districts, a total of
95.3% of women in the 15 - 24-year age group, 97.5% in the 25 -
34-year group and 98% in the 35 - 45-year age group were
immune to rubella.  Using the chi-square test no statistically
significant difference in the rate of rubella susceptibility was
found between the 4 districts tested. 
Discussion
Rubella vaccine is not part of the EPI schedule in South Africa
and rubella virus continues to circulate freely. This study
shows that by the time women in the Western Cape reach
childbearing age, taken to be 15 years, 95.3% are immune to
rubella. Similar prevalence rates were seen in all 4 districts
sampled. This study was not powered to assess differences in
rubella susceptibility among different racial groups in the
province or to look for ‘pockets’ of increased rubella-
susceptible women. At first glace the high level of immunity
may seem reassuring; however, at the time of reaching
childbearing age nearly 1 in 20 women in the Western Cape
(4.7%) remain susceptible in an environment with freely
circulating wild-type rubella. These patients are at substantial
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Table I. Seroprevalence of rubella antibodies, Western
Cape (excluding Central Karoo district)
Age group Number Number 95% confidence
(yrs) tested immune (%) interval (%)
15 - 24 600 572 (95.3) 93.33 - 96.88
25 - 34 400 390 (97.5) 95.45 - 98.79
35 - 45 200 196 (98.0) 94.96 - 99.45
Total 1 200 1 158 (96.5) 95.30 - 97.47
Table II. Seroprevalence of rubella immunity in the 4 districts tested
Age West Coast/ 95% South Coast/ 95% 95%
group Number Metropolitan 95% confidence Winelands confidence Klein confidence Boland confidence
(yrs) tested (%) interval (%) (%) interval (%) Karoo (%) interval (%) (%) interval (%)
15 - 24 150 141 (94.0) 88.92 - 97.22 142 (94.7) 89.76 - 97.67 145 (96.7) 92.39 - 98.91 144 (96.0) 91.50 - 98.52
25 - 34 100 96 (96.0) 90.07 - 98.90 97 (97.0) 91.48 - 99.38 100 (100) 96.38 - 100* 97 (97.0) 91.48 - 99.37
35 - 45 50 48 (96.0) 86.29 - 99.51 49 (98.0) 89.35 - 99.95 49 (98.0) 89.35 - 99.95 50 (100) 92.90 - 100*
* One sided, 97.5% confidence interval. 
Fig. 1. Districts of the Western Cape as in the HIV/syphilis antenatal
survey.8 (Source: Migration Study in the Western Cape 2001,
Provincial Government of the Western Cape.12)
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risk of primary rubella infection. Although there was no
statistically significant difference in rubella susceptibility
between the age groups (p = 0.085), using the non-parametric
test for trend the observable increase in rubella immunity from
95.3% in the 15 - 24-year age group to 98% in the 35 - 45-year
age group could be indicative of primary rubella infection
occurring in women of childbearing age (p = 0.04). However,
this interpretation is limited by the cross-sectional nature of the
study.  The data from this study are corroborated by data
‘mined’ from Groote Schuur Hospital’s infertility clinic, which
showed a rubella susceptibility rate of 4.97% among 1 139
patients screened from April 2002 to October 2004. These
patients are routinely tested for immunity to rubella as part of
their initial assessment. 
Rubella infections tend to occur in late spring/summer and
our laboratory has seen a consistent peak in the number of new
congenital rubella cases during the winter months (6 - 9
months after seasonal peaks).  
An additional point to consider is that exposed pregnant
women with low-level immunity to rubella can be reinfected in
the face of circulating wild-type rubella. The risk of fetal
infection is approximately 8% following reinfection in the first
16 weeks of pregnancy, but fetal malformations are rare.10
Rubella vaccine has not been recommended for inclusion in
the EPI in many developing countries because where sustained
high coverage cannot be guaranteed, its introduction could
paradoxically increase the number of susceptible young
women by slowing but not interrupting virus transmission and
thus shifting the age of first exposure into the reproductive
years.11 Private-sector MMR vaccination in South Africa creates
the same potential hazard.6
Vaccination, however, is the only way of preventing
congenital rubella. Two vaccination strategies may be
implemented. A selective vaccination programme prevents CRS
by vaccinating adolescent girls and women while allowing
rubella to continue circulating. Universal vaccination of
children has the aim of eliminating both rubella and CRS and
has been shown to be the more successful strategy. Initially a
combined approach would be the most prudent in South Africa
as the impact on CRS prevention would be immediate. 
Before authorities can consider including rubella vaccine in
the EPI (SA), more information is needed on rubella
seroprevalence in women of childbearing age in other
provinces in South Africa. In addition, formal rubella and CRS
surveillance need to be implemented. This information will
provide a more scientific foundation for recommending that
rubella vaccine be included in the national schedule. The
magnitude of congenital rubella is underappreciated in South
Africa and a concerted effort needs to be made to provide the
data that will assist in its control. Even with the limitations of
this small cross-sectional study, it is an important step in
addressing the issue of seroprevalence of rubella antibodies in
South Africa and in beginning to deal with this public health
problem. 
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